Suppr超能文献

[新型冠状病毒肺炎患者的预防和抗血栓治疗指南。拉丁美洲止血与血栓形成合作组织(CLAHT)共识]

[Guidelines for prophylaxis and anti-thrombotic treatment for patients with COVID-19. Consensus of the Latin American Cooperative Group on Hemostasis and Thrombosis (CLAHT)].

作者信息

Guillermo-Esposito Cecilia, Casais Patricia, Cesarman-Maus Gabriela, Andrade-Orsi Fernanda, Martínez-Rovira Rosario, de-Campos-Guerra Joao C, Rezende Suely M, Izaguirre-Ávila Raúl, Altman Raúl, Ceresetto José, Colorio Cecilia, Duboscq Cristina, Rosa Claudio Martín, Molnar Soledad, García Diana, Tejarina Mario Luis, García Nelson Nina, Choque Pacheco Juan, J. María Chiara Chindamo, Ramos Ramos Gloria, León Basantes Guillermo, Milena Reyna Aura, Cantero Guevara Miriam, Porres Aguilar Mateo, Meillón Luis, Grimaldo Flavio Adrián, Bacon Fonseca Ludwing Alexander, Ávila Milord Al, Aguilar Ricardo, Aparicio Rafael, de Guggiari Paula, Chumpitaz Gloria, García Pedro Pablo, Steffano Blanca, Damiano Sandra, Serrano Juan, Zavahra Marisol

机构信息

Cátedra de Hematología, Facultad de Medicina, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay.

Departamento de Epidemiología Clínica y Evidencia, Instituto de Investigaciones en Salud Pública, Universidad de Buenos Aires, Argentina.

出版信息

Arch Cardiol Mex. 2021 Dec 20;91(Suplemento COVID):047-054. doi: 10.24875/ACM.20000291.

Abstract

Coagulopathy and thrombosis associated with coronavirus disease 2019 (COVID-19) represent a major issue in the management of this disease. In the past months, clinical studies have demonstrated that COVID-19 patients present with a particular hypercoagulable state, in which a markedly increased D-dimer concomitant with increased levels of fibrinogen are observed. This hypercoagulable state leads to an increased risk of thrombosis, which seems to be higher among those patients with critical symptoms of COVID-19. The best therapeutic approach to prevent thrombotic events in COVID-19 has not been determined yet and several questions regarding thromboprophylaxis therapy, such as the time to initiate anticoagulation, type of anticoagulant and dose regimen, have emerged among physicians. To address these concerns, several medical societies have published position papers to provide the opinion of thrombosis experts on the management of coagulopathy and thrombosis associated with COVID-19. In line with this, the Latin America Cooperative Group of Hemostasis and Thrombosis (Grupo CLAHT) has constituted a panel of experts in thrombosis and hemostasis to discuss the available data on this topic. The aim of this review is to summarize the current evidence regarding hemostatic impairment and thrombotic risk in COVID-19 and to provide a carefully revised opinion of Latin American experts on the thromboprophylaxis and management of thrombotic events and coagulopathy in patients with suspected COVID-19.

摘要

2019冠状病毒病(COVID-19)相关的凝血病和血栓形成是该疾病治疗中的一个主要问题。在过去几个月里,临床研究表明,COVID-19患者呈现出一种特殊的高凝状态,其中观察到D-二聚体显著增加,同时纤维蛋白原水平也升高。这种高凝状态导致血栓形成风险增加,在COVID-19重症患者中似乎更高。目前尚未确定预防COVID-19血栓事件的最佳治疗方法,医生们也提出了一些关于血栓预防治疗的问题,比如开始抗凝的时间、抗凝剂类型和剂量方案。为了解决这些问题,一些医学协会发表了立场文件,以提供血栓形成专家对COVID-19相关凝血病和血栓形成管理的意见。与此一致,拉丁美洲止血与血栓形成合作组织(Grupo CLAHT)成立了一个血栓形成和止血专家小组,以讨论该主题的现有数据。本综述的目的是总结目前关于COVID-19止血功能障碍和血栓形成风险的证据,并提供拉丁美洲专家对疑似COVID-19患者血栓预防、血栓事件管理和凝血病的审慎修订意见。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f058/10161848/80e182381837/ACM-91-47-g001.jpg

相似文献

2
COVID-19 Infection: Viral Macro- and Micro-Vascular Coagulopathy and Thromboembolism/Prophylactic and Therapeutic Management.
J Cardiovasc Pharmacol Ther. 2021 Jan;26(1):12-24. doi: 10.1177/1074248420958973. Epub 2020 Sep 14.
8
COVID-19-associated coagulopathy in children: A multicenter observational cohort study.
Pediatr Blood Cancer. 2023 Jan;70(1):e30079. doi: 10.1002/pbc.30079. Epub 2022 Nov 3.
10
Anticoagulation for COVID-19 Patients: A Bird's-Eye View.
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211039288. doi: 10.1177/10760296211039288.

引用本文的文献

1
Endothelium dysfunction and thrombosis in COVID-19 with type 2 diabetes.
Endocrine. 2023 Oct;82(1):15-27. doi: 10.1007/s12020-023-03439-y. Epub 2023 Jul 1.

本文引用的文献

1
A proposal for staging COVID-19 coagulopathy.
Res Pract Thromb Haemost. 2020 Jul 6;4(5):731-736. doi: 10.1002/rth2.12372. eCollection 2020 Jul.
2
Pulmonary embolism response teams in the challenging era of venous thromboembolism associated with COVID-19.
J Vasc Surg Venous Lymphat Disord. 2020 Sep;8(5):898-899. doi: 10.1016/j.jvsv.2020.04.032. Epub 2020 Jun 1.
4
Incidence of venous thromboembolism in hospitalized patients with COVID-19.
J Thromb Haemost. 2020 Aug;18(8):1995-2002. doi: 10.1111/jth.14888. Epub 2020 Jul 27.
5
High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.
Intensive Care Med. 2020 Jun;46(6):1089-1098. doi: 10.1007/s00134-020-06062-x. Epub 2020 May 4.
6
Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy.
Thromb Res. 2020 Jul;191:9-14. doi: 10.1016/j.thromres.2020.04.024. Epub 2020 Apr 23.
8
ISTH interim guidance on recognition and management of coagulopathy in COVID-19.
J Thromb Haemost. 2020 May;18(5):1023-1026. doi: 10.1111/jth.14810. Epub 2020 Apr 27.
10
High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.
J Thromb Haemost. 2020 Jul;18(7):1743-1746. doi: 10.1111/jth.14869. Epub 2020 May 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验